The Hope Foundation for Cancer Research

@supportingswog.bsky.social

Public charity supporting SWOG Cancer Research Network, part of the NCI’s National Clinical Trials Network thehopefoundation.org @swog.org #SWOGonc

Heartland Cancer Research NCORP is one of @swog.org's top enrollers, serving patients in 5 states & exemplifying community-based research that keeps care close to home w/access to high-quality clinical trials. Amazing members who have reg. more than 4,000 #SWOGonc participants! tinyurl.com/54eemzeu

SWOG Member Highlight: Heartland NCORP | SWOG

SWOG’s NCORP member sites are essential contributors in the group’s commitment to bring clinical trial opportunities to all patients affected by cancer and to ensure our trials enroll cohorts broadly ...

tinyurl.com

Team Hope showed up and gave it their all! 62 or 32 miles through the hills (and wind!) at the #TourDeScottsdale Every mile 🚴‍♀️ to advance @swog.org research #SWOGonc Proud of this crew! Grateful for everyone who donated & cheered us on 🙌 Watch the recap ⬇️ vimeo.com/1180550865?f...

Team Hope at the 2026 Tour de Scottsdale

The Hope Foundation's 3rd annual Team Hope Ride at the 2026 Tour de Scottsdale.

vimeo.com

March 20, 2026: FDA approves nivolumab + AVD combination for Stage III or IV classical Hodgkin lymphoma in patients 12 and older, based on results of phase 3 S1826 #NCTN NCI trial, led by SWOG Cancer Research Network @swog.org and Children's Oncology Group (COG): www.fda.gov/drugs/resour...

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

FDA approved approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for cHL.

fda.gov

The @swog.org Front Line: The Next Era of SWOG Success tinyurl.com/336jff53 "We’ll continue the group’s exemplary work as an NCTN leader in precision medicine, in the innovative study of rare cancers, and in so much more, including in pragmatic, highly efficient trials." Learn more 5/1 #SWOGonc

The Next Era of SWOG Success | SWOG

In our vision, SWOG’s next era of success grows from our current one. We’ll continue the group’s exemplary work as an NCTN leader in precision medicine, in the innovative study of rare cancers, and in...

swog.org